نتایج جستجو برای: arsenic trioxide

تعداد نتایج: 19257  

Journal: :Haematologica 2011
Emanuele Ammatuna Pau Montesinos Syed Khizer Hasan Safaa M Ramadan Jordi Esteve Maximillian Hubmann Maria Pagoni David Grimwade Miguel Angel Sanz Francesco Lo-Coco

We report the clinical features and treatment outcome of 33 patients with multiple sclerosis who developed acute promyelocytic leukemia. Thirty patients were previously exposed to mitoxantrone. The median latency period between treatment initiation and acute promyelocytic leukemia diagnosis was 32 months. The PML-RARA bcr1 iso-form was identified in 87% of cases. Twenty-nine (90%) patients achi...

Journal: :Cellular & molecular immunology 2006
Ke Hong Bi Guo Sheng Jiang

Leukocytosis or hyperleukocytosis occurs during ATRA or arsenic trioxide differentiation therapy, which is related to the RA syndrome. The number of WBC often increased by ten or more times as high as that of pretreatment, around 7 to 20 days after treatment with ATRA or arsenic trioxide. Usually, when number of WBC tended to peak, there was concomitance with down-regulation of promyelocytes, u...

Journal: :Cancer research 1999
Y S Lew S L Brown R J Griffin C W Song J H Kim

To investigate the antitumor action of arsenic trioxide in solid tumors, we carried out quantitative tumor perfusion studies, using locally advanced methylcholanthrene-induced fibrosarcoma grown in BALB/c mice. The tumor perfusion studies were assessed by two separate methods: 99mTc clearance and 86Rb uptake. A single administration of arsenic trioxide (10 mg/kg i.p.) produced a preferential va...

Journal: :Acta pharmacologica Sinica 2003
Huai-Yu Wang Shan-Xi Liu Mei Zhang

AIM To investigate the gene expression profiles of acute promyelocytic leukemia (APL) cell line NB4 treated with arsenic trioxide (As2O3) using cDNA microarray. METHODS Two cDNA probes were prepared through reverse transcription from mRNA of NB4 cells treated with or without arsenic trioxide. The probes were labeled with Cy3 and Cy5 fluorescence dyes individually, hybridized with cDNA microar...

Journal: :international journal of hematology-oncology and stem cell research 0
mozaffar aznab imam reza and taleghani hospitals, kermanshah university of medical sciences, kermanshah, iran kamran alimoghadam hematology-oncology and stem cell research center, tehran university of medical sciences, tehran, iran ardeshir ghavamzadeh hematology-oncology and stem cell research center, tehran university of medical sciences, tehran, iran ghobad salimi jafar navabi mari attai

introduction: arsenic has been used as an effective medicine in the treatment of severe promyelocytic leukemia in recurrence and resistance cases toward atra. in this study, it has been used as induction and maintenance therapy after remission. method & material: we studied 31 patients diagnosed by apl. a rsenic was started at a dose of 0.15 mg/kg (daily) until patient’s bone marrow remission.(...

2010
Charles Francis Hall Yuan Jia

Arsenic poisoning interferes with cellular longevity by allosteric inhibition of an essential metabolic enzyme pyruvate dehydrogenase (PDH) complex which catalyzes the reaction Pyruvate + CoA-SH + NAD+ PDH Acetyl-Co-A + NADH + CO2. With the enzyme inhibited, the energy system of the cell is disrupted resulting in a cellular apoptosis episode. Biochemically, arsenic prevents use of thiamine resu...

2017
Claudia Paret Alexandra Russo Henrike Otto Arnulf Mayer Sebastian Zahnreich Wolfgang Wagner David Samuel David Scharnhorst David A. Solomon Girish Dhall Kenneth Wong Hannah Bender Francesca Alt Arthur Wingerter Marie A. Neu Olaf Beck Dirk Prawitt Stefan Eder Nicole Henninger Khalifa El Malki Nadine Lehmann Nora Backes Lea Roth Larissa Seidmann Clemens Sommer Marc A. Brockmann Gundula Staatz Heinz Schmidberger Jörg Faber

High-grade neuroepithelial tumor of the central nervous system with BCOR alteration (HGNET-BCOR) is a rare, highly malignant tumor. At the time of this publication, no standard protocol exists to treat this tumor entity. In this work, we tested the responsiveness of the primary culture PhKh1 derived from tumor tissue from a pediatric HGNET-BCOR patient (P1) to inhibitors of the Sonic hedgehog p...

2016
Ye Zhang SiJing Wu Dan Luo JianFeng Zhou DengJu Li Ken Mills

AIM All-trans retinoic acid combined to anthracycline-based chemotherapy is the standard regimen of acute promyelocytic leukemia. The advent of arsenic trioxide has contributed to improve the anti-leukemic efficacy in acute promyelocytic leukemia. The objectives of the current study were to evaluate if dual induction by all-trans retinoic acid and arsenic trioxide could accelerate the recovery ...

Journal: :Archives of Iranian medicine 2011
Kamran Alimoghaddam Ardeshir Ghavamzadeh Mohamad Jahani Asadolah Mousavi Masoud Iravani Shahrbano Rostami Hamidolah Ghaffari Roholah Hosseini Mehdi Jalili

BACKGROUND Although standard first line treatment of acute promyelocytic leukemia is All trans retinoic acid (ATRA) and chemotherapy, some patients relapse and need a second line of treatment. Relapsed cases of promyelocytic leukemia can be salvaged with arsenic trioxide. METHODS Between May 1999 and Jan. 2010, we treated 31 relapsed cases of promyelocytic leukemia with arsenic trioxide. Thes...

2006
Clement G. Yedjou Pamela Moore Paul B. Tchounwou

The treatment of acute promyelocytic leukemia (APL) has been based on the administration of all-trans retinoic acid plus anthracycline chemotherapy, which is very effective as first line therapy; however 25 to 30% of patients will relapse with their disease becoming refractory to conventional therapy. Recently, studies have shown arsenic trioxide to be effective in the treatment of acute promye...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید